Table 3.
Reasons for discontinuation according to therapy
| Reason for discontinuation | DMF (n = 439) | IFN (n = 439) | DMF (n = 535) | GA (n = 535) | DMF (n = 388) | TERI (n = 388) | DMF (n = 457) | FTY all-comer (n = 457) | DMF (n = 99) | FTY label (n = 99) |
|---|---|---|---|---|---|---|---|---|---|---|
| Total number of discontinuations | 117 | 193 | 150 | 226 | 100 | 83 | 136 | 115 | 37 | 19 |
| Adverse event | 47 (40.2%) | 54 (28.0%) | 57 (38.0%) | 49 (21.7%) | 49 (49.0%) | 43 (51.8%) | 57 (41.9%) | 28 (24.3%) | 10 (27.0%) | 6 (31.6%) |
| Fatigue | 0 (0.0%) | 2 (1.0%) | 0 (0.0%) | 1 (0.4%) | – | – | – | – | – | – |
| Lack of efficacy | 13 (11.1%) | 40 (20.7%) | 23 (15.3%) | 44 (19.5%) | 6 (6.0%) | 18 (21.7%) | 21 (15.4%) | 14 (12.2%) | 11 (29.7%) | 4 (21.1%) |
| Non-medical (patient decision) | 43 (36.8%) | 86 (44.6%) | 51 (34.0%) | 104 (46.0%) | 34 (34.0%) | 18 (21.7%) | 44 (32.4%) | 57 (49.6%) | 11 (29.7%) | 4 (21.1%) |
| Pregnancy or planned pregnancy | 6 (5.1%) | 8 (4.1%) | 12 (8.0%) | 19 (8.4%) | 4 (4.0%) | 3 (3.6%) | 6 (4.4%) | 12 (10.4%) | 4 (10.8%) | 5 (26.3%) |
| Freedom from disease activity | – | – | – | – | – | – | 0 (0.0%) | 1 (0.9%) | – | – |
| Missing | 8 (6.8%) | 3 (1.6%) | 7 (4.7%) | 9 (4.0%) | 7 (7.0%) | 1 (1.2%) | 8 (5.9%) | 3 (2.6%) | 1 (2.7%) | 0 (0.0%) |
Data are number (proportion out of total discontinuations, %) per therapy
DMF delayed-release dimethyl fumarate, FTY fingolimod, GA glatiramer acetate, IFN interferons, TERI teriflunomide